To read this content please select one of the options below:

Evergreen Enhancement

Publication date: 20 January 2017

Abstract

Richard Alpert, senior partner at Evergreen Investments, must decide which of his two best employees to promote to the position of managing VP. He had initially preferred Charlie Pace over Daniel Faraday, but that decision had become less clear-cut when Alpert inadvertently overheard an office conversation and learned that Pace was taking Adderall, a stimulant primarily prescribed for people suffering from attention deficit/hyperactivity disorder (ADHD). Pace did not have ADHD and apparently obtained the medication by deceiving a physician. Alpert is faced with a number of questions, including whether it was fair to Faraday—or any other high-performing employee—to be passed over for promotion in favor of someone who illicitly boosted his performance with a substance he did not medically need.

Keywords

Citation

Harris, J.D. and Mead, J. (2017), "Evergreen Enhancement", . https://doi.org/10.1108/case.darden.2016.000113

Publisher

:

University of Virginia Darden School Foundation

Copyright © 2012 by the University of Virginia Darden School Foundation, Charlottesville, VA. All rights reserved.

Related articles